Affinage

Showing IL1RL1ST2L is a alias.

IL1RL1

Interleukin-1 receptor-like 1 · UniProt Q01638

Length
556 aa
Mass
63.4 kDa
Annotated
2026-06-10
100 papers in source corpus 31 papers cited in narrative 32 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IL1RL1 (ST2) encodes the receptor system for the alarmin IL-33 and operates as a central node coordinating type 2 immunity, tissue protection, and fibrosis across multiple organs (PMID:17492053, PMID:24982172, PMID:37063913). The gene produces a transmembrane signaling receptor (ST2L) that pairs with IL-1 receptor accessory protein (IL-1RAcP/IL1RAP) to transduce IL-33 binding into MyD88-dependent NF-κB and MAPK activation (PMID:23999434, PMID:26518437), and a soluble isoform (sST2) that functions as a decoy sequestering IL-33 to limit signaling (PMID:17492053, PMID:27699235). Beyond these, additional membrane-anchored (ST2V) and secreted (ST2LV) splice variants arise from the locus (PMID:11478810, PMID:15566939), and expression is controlled at the promoter by PU.1, epigenetically via Setd2-deposited H3K36me3, developmentally by TGF-β–MEK signaling, and by transcription-factor circuits (Bcl6/Blimp1) and enhancer variants (PMID:31911623, PMID:22824976, PMID:37117777, PMID:36463230, PMID:32179158). Through cell-intrinsic signaling in ILC2s, Tregs, mast cells, microglia, and memory TH2 cells, IL-33/ST2 drives type 2 cytokine production, mast cell survival via BCLXL, microglial IL-10-dependent neuroprotection, and the establishment of lung-resident memory responses (PMID:24982172, PMID:33095261, PMID:28389473, PMID:37063913, PMID:36720287). In the heart, IL-33 produced by mechanically strained fibroblasts signals to cardiomyocytes through ST2L as an antihypertrophic, antifibrotic paracrine system, while sST2 independently activates cardiac fibroblasts and collagen synthesis via NRP-1/NF-κB (PMID:17492053, PMID:32664340). The pathway also promotes immunosuppressive and tumor-supportive states—expanding ST2+ tumor-associated macrophages, coupling Tregs to cancer-associated fibroblasts through the AREG-EGFR axis, and sustaining leukemia and glioma stem-cell programs via Wnt/MAPK/NF-κB and tenascin-C (PMID:32664340, PMID:37611111, PMID:32376804, PMID:31889095, PMID:37643244). An ST2-independent branch exists in which oxidised IL-33 engages a RAGE/EGFR complex on airway epithelium to drive remodeling (PMID:37442582). Enhancer and TIR-domain coding variants in IL1RL1 modulate sST2 levels and IL-33 responsiveness, linking the locus to airway type 2 inflammation and to Alzheimer's disease risk in APOE-ε4 female carriers (PMID:23999434, PMID:27699235, PMID:32324168, PMID:37117777).

Mechanistic history

Synthesis pass · year-by-year structured walk · 31 steps
  1. 2007 High

    Established IL-33 as the functional ligand for ST2L and defined the receptor's antihypertrophic, cardioprotective role, with sST2 acting as a decoy—resolving the long-standing orphan-receptor status of ST2.

    Evidence ST2-knockout mice under transverse aortic constriction with recombinant IL-33 rescue and cardiomyocyte NF-κB/IκBα signaling assays; mechanical stretch of cardiac fibroblasts in coculture

    PMID:17492053

    Open questions at the time
    • Direct structural basis of IL-33/ST2L binding not addressed
    • Relative contribution of sST2 decoy vs. ST2L signaling in vivo not separated
  2. 1997 Medium

    Showed that ST2 isoforms are differentially regulated—soluble ST2 induced by inflammatory stimuli while membrane ST2 is constitutive—establishing isoform-specific regulation before the ligand was known.

    Evidence Northern/Western blotting with cytokine and PMA treatment of BALB/c-3T3 cells and a UVB irradiation mouse model

    PMID:9207179

    Open questions at the time
    • Functional consequence of induced sST2 not defined at the time
    • No ligand context
  3. 2001 Medium

    Identified ST2V, a membrane-localized splice variant with gut-restricted expression, expanding the isoform repertoire of the IL1RL1 locus.

    Evidence RT-PCR tissue distribution, COS7 transfection, subcellular fractionation, and confocal microscopy

    PMID:11478810

    Open questions at the time
    • No signaling function assigned to ST2V
    • No ligand interaction tested
  4. 2004 Medium

    Characterized ST2LV, a secreted N-glycosylated splice variant lacking the transmembrane domain, further demonstrating alternative-splicing diversity at the locus.

    Evidence RT-PCR cloning, COS-7 transfection with radiolabeling, and PNGase F deglycosylation in chicken

    PMID:15566939

    Open questions at the time
    • Mammalian relevance of ST2LV not established
    • No functional/signaling role assigned
  5. 2012 Medium

    Defined transcriptional control of ST2 by identifying PU.1 as a direct activator of the human promoter in mast cells and basophils, providing a lineage-specific expression mechanism.

    Evidence Promoter reporter mutagenesis, EMSA, and siRNA knockdown of PU.1 in LAD2 and KU812 cells

    PMID:22824976

    Open questions at the time
    • Whether PU.1 controls isoform choice (sST2 vs ST2L) not addressed
    • Other lineage-specific regulators not excluded
  6. 2012 Medium

    Demonstrated that soluble ST2 functionally suppresses Th2 cytokine output and allergic airway eosinophilia, confirming the decoy function in an allergic disease context.

    Evidence In vitro splenocyte stimulation and in vivo mST2 gene transfer in OVA-sensitized asthma mice with BAL cytokine/eosinophil quantification

    PMID:12372135

    Open questions at the time
    • Mechanism of cytokine selectivity (IL-4/IL-5 vs IFN-γ) unexplained
    • Endogenous sST2 dynamics not measured
  7. 2013 Medium

    Resolved the receptor architecture by showing ST2L partners with IL-1RAcP to drive NF-κB/MAPK, and linked TIR-domain coding variants to altered sST2 levels and IL-33 responsiveness.

    Evidence Cell-culture expression of IL1RL1 missense variants with sST2 quantification combined with GWAS of the Framingham Offspring Cohort

    PMID:23999434

    Open questions at the time
    • Stoichiometry of the ST2L–IL-1RAcP complex not defined
    • Causal disease mechanism of variants beyond signaling not fully resolved
  8. 2014 High

    Identified BCLXL as the downstream effector by which IL-33/ST2 promotes mast cell survival, establishing a cell-intrinsic pro-survival function.

    Evidence ST2-KO mice across multiple tissues, in vitro apoptosis assays with BCLXL inhibition/knockdown, and peritoneal mast cell adoptive transfer

    PMID:24982172

    Open questions at the time
    • Signaling steps linking ST2L to BCLXL induction not mapped
    • Relevance to other ST2+ lineages not tested
  9. 2015 High

    Dissected cell-type-specific Treg functions of ST2, showing it is dispensable for tissue accumulation but required for type 2 cytokine production and for restraining pathogenic γδT cells in neuroinflammation.

    Evidence Foxp3-Cre conditional ST2 knockout in the EAE model with flow cytometry and cytokine measurement

    PMID:33095261

    Open questions at the time
    • Downstream signaling distinguishing accumulation vs effector function not defined
    • Mechanism limiting γδT cells indirect
  10. 2015 High

    Positioned IL-33/ST2 as an amplifier of pathogenic T-cell hyperactivation via MyD88, demonstrating a disease-driving role in hemophagocytic lymphohistiocytosis.

    Evidence ST2 blockade in perforin-deficient LCMV-infected mice with survival and IFNγ+ T-cell readouts

    PMID:26518437

    Open questions at the time
    • Direct cellular target of ST2 signaling in this setting not pinpointed
    • Contribution of sST2 vs ST2L not separated
  11. 2016 Medium

    Showed that IL1RL1 risk SNPs act as tissue-specific eQTLs regulating lung sST2 output, mechanistically linking genetic variation to the IL-33-neutralizing reservoir and asthma risk.

    Evidence eQTL analysis in airway epithelium and lung parenchyma, plasma sST2 measurement, and IL-33 neutralization assays in asthmatic cohorts

    PMID:27699235

    Open questions at the time
    • Causal cell type producing sST2 in lung not fully resolved
    • Effect sizes additive but mechanism of additivity unclear
  12. 2017 High

    Identified IL-10 as the protective downstream mediator of microglial IL-33/ST2 signaling after ischemic stroke, defining a neuroprotective axis.

    Evidence ST2-KO mice in two stroke models, ICV IL-33 infusion, microglial cocultures, and IL-10 KO mice

    PMID:28389473

    Open questions at the time
    • Signaling steps from ST2 to IL-10 induction not mapped
    • M1/M2 polarization mechanism downstream of ST2 incomplete
  13. 2017 Medium

    Revealed an IL-1β/IL-33 amplification loop between microglia and oligodendrocytes that drives neuroinflammation in cerebral malaria, contrasting with the protective stroke role.

    Evidence ST2-KO mice in P. berghei ANKA infection, cell-type-specific in vitro stimulation, and cognitive/neurogenesis assays

    PMID:28448579

    Open questions at the time
    • Context-dependence of protective vs pathogenic CNS outcomes unexplained
    • Direct ST2-expressing cell driving the loop not isolated
  14. 2018 Medium

    Identified the lung (type II pneumocytes) as a major strain-responsive source of sST2 in heart failure, refining where the circulating biomarker originates.

    Evidence Ischemic heart failure model time-course, primary human type II pneumocyte strain cultures, and bronchial aspirate sST2 measurement

    PMID:30562096

    Open questions at the time
    • Signaling linking mechanical strain to sST2 secretion not defined
    • Relative lung vs cardiac contribution to plasma sST2 unresolved
  15. 2019 High

    Established sST2 as an active profibrotic effector, not merely a decoy, by showing it drives cardiac fibroblast activation through NRP-1/NF-κB.

    Evidence Proteomics of sST2-treated human cardiac fibroblasts with NF-κB inhibition, NRP-1 siRNA/overexpression, and pressure-overload rat correlation

    PMID:32664340

    Open questions at the time
    • Receptor mediating sST2 signaling on fibroblasts not identified
    • Reconciliation with sST2 decoy function not addressed
  16. 2019 Medium

    Extended ST2 function to tumor immunosuppression, showing IL-33/ST2 expands CXCR3-driven ST2+ TAMs and synergizes negatively with anti-PD-1 in colorectal cancer.

    Evidence ST2-KO mice, CRC models, IL-33 trap, and combination anti-PD-1 therapy

    PMID:32376804

    Open questions at the time
    • Direct ST2 signaling in TAMs vs indirect recruitment not separated
    • CXCR3 ligand source not defined
  17. 2019 Medium

    Demonstrated a tumor-cell-intrinsic role in glioma, where IL-33/ST2/NF-κB upregulates tenascin-C to drive invasion.

    Evidence IL-33 treatment/knockdown in glioma cells, NF-κB and TNC assays, and in vitro/xenograft invasion assays

    PMID:31889095

    Open questions at the time
    • Whether ST2L or a variant transduces the signal not specified
    • In vivo TNC dependence partially inferred
  18. 2019 Medium

    Linked IL1RL1 to leukemia stem cell survival and chemoresistance, marking IL1RL1+ LSCs as a pro-survival, treatment-resistant population.

    Evidence Cbfb-MYH11 knock-in mouse model with in vitro replating/pro-survival assays and in vivo chemotherapy survival of sorted IL1RL1+/- cells

    PMID:30742053

    Open questions at the time
    • Pro-survival effectors not molecularly identified here
    • Source of IL-33 in the niche unclear
  19. 2019 Medium

    Dissociated ST2 from IL-33 in cardiac fibrosis, showing ST2 (but not IL-33) loss drives periarteriolar fibrosis, implying ligand-independent or alternative-ligand ST2 functions.

    Evidence Parallel IL-33-KO and ST2-KO mice under TAC and aged WT mice with histomorphometric fibrosis quantification

    PMID:30763587

    Open questions at the time
    • Alternative ST2 ligand or ligand-independent mechanism not identified
    • Cell type responsible not pinpointed
  20. 2020 Medium

    Defined developmental regulation of IL1RL1, showing TGF-β via MEK upregulates ST2 in ILC2 progenitors and is needed for ILC2 development.

    Evidence TGF-βRII conditional KO in bone marrow progenitors with MEK inhibition and IL1RL1 mRNA measurement

    PMID:31911623

    Open questions at the time
    • Direct transcriptional link from MEK to IL1RL1 not shown
    • Other progenitor signals not excluded
  21. 2020 High

    Identified a helminth immune-evasion protein (HpBARI) that directly binds and masks ST2, validating ST2 as a druggable surface target across species.

    Evidence Direct binding assays, cell-surface ST2 detection, in vitro/in vivo asthma models, and human PBMC IL-33 response assays

    PMID:32420871

    Open questions at the time
    • Binding interface/structural epitope not resolved
    • Effect on ST2L vs sST2 not separated
  22. 2020 Medium

    Provided mechanistic insight into how IL1RL1 TIR-domain coding variants alter IL-33-driven NF-κB signaling without affecting TLR signaling, isolating receptor-specific effects.

    Evidence Primary bronchial epithelial cells with IL-33 stimulation, NF-κB reporter assays, and TLR signaling controls

    PMID:32324168

    Open questions at the time
    • Structural basis of variant effect on TIR signaling not defined
    • Downstream gene expression consequences not fully mapped
  23. 2020 High

    Showed Bcl6/Blimp1 reciprocally control ST2+ Treg development, with ST2+ Tregs producing type 2 cytokines and exacerbating allergic airway inflammation.

    Evidence Bcl6 and Blimp1 Foxp3-Cre conditional KOs, house dust mite model, and T-cell transfer with ST2-deficiency validation

    PMID:32179158

    Open questions at the time
    • Direct transcriptional regulation of IL1RL1 by Blimp1 not shown
    • How ST2+ Tregs switch to pro-inflammatory output not detailed
  24. 2020 High

    Established that cell-intrinsic ST2 in ILC2s is non-redundant for IL-33 (but not IL-25) responsiveness, type 2 cytokine output, and eosinophil homeostasis.

    Evidence Nmur1-iCre conditional ST2 knockout in ILC2s with allergic lung inflammation and N. brasiliensis infection models

    PMID:37063913

    Open questions at the time
    • Signaling distinguishing IL-33 vs IL-25 pathways in ILC2s not detailed
    • Persistence/memory of activated ILC2s not addressed
  25. 2022 Medium

    Revealed epigenetic control of IL1RL1 by Setd2-deposited H3K36me3 at promoters and intragenic enhancers, required for GATA3+ST2+ intestinal Treg identity and suppressive function.

    Evidence Foxp3-Cre Setd2 conditional KO with H3K36me3 ChIP, expression profiling, and human Treg manipulation

    PMID:36463230

    Open questions at the time
    • Direct vs indirect Setd2 effect on the IL1RL1 locus not fully separated
    • Other Setd2 target genes contributing not excluded
  26. 2023 High

    Discovered an ST2-independent IL-33 pathway in which oxidised IL-33 engages a RAGE/EGFR complex to drive airway remodeling, broadening IL-33 receptor biology beyond ST2.

    Evidence Epithelial damage assays, 3D ALI cultures from healthy and COPD donors, transcriptomics, IL-33 neutralization, and RAGE-EGFR co-IP

    PMID:37442582

    Open questions at the time
    • Relative contributions of ST2 vs RAGE/EGFR pathways in vivo unclear
    • Trigger for IL-33 oxidation not defined
  27. 2023 Medium

    Defined a Treg-CAF immunosuppressive circuit in tumors, where IL1RL1 signaling drives Treg-derived AREG acting on CAF EGFR, and showed blockade enhances IL-33/PD-1 antitumor therapy.

    Evidence scRNA-seq, in vivo AREG mAb blockade, genetic IL1RL1 deficiency in Tregs, and PD-1 combination tumor experiments

    PMID:37611111

    Open questions at the time
    • Direct signaling from ST2 to AREG induction not mapped
    • Generalizability across tumor types not established
  28. 2023 High

    Identified an anti-ferroptotic function of IL-33/ST2 in endometrial stromal cells via P38/JNK–ATF3–SLC7A11, extending ST2 biology to cell-death regulation in endometriosis.

    Evidence Stromal-macrophage coculture, erastin ferroptosis assays, ATF3 manipulation, SLC7A11 quantification, P38/JNK inhibition, and an endometriosis mouse model

    PMID:37816731

    Open questions at the time
    • Receptor isoform mediating the effect not specified
    • Link between ST2 and P38/JNK activation step not detailed
  29. 2023 High

    Established the enhancer variant rs1921622 as a causal regulator of sST2 levels and linked reduced sST2 to lower Alzheimer's risk in APOE-ε4 female carriers via microglial Aβ handling.

    Evidence CRISPR-Cas9 editing of the rs1921622 enhancer, Mendelian randomization, and brain immunohistochemistry/microglial assays

    PMID:37117777

    Open questions at the time
    • Mechanism linking sST2 to microglial Aβ clearance not fully resolved
    • Sex- and APOE-specificity mechanism unexplained
  30. 2023 High

    Demonstrated a cell-autonomous IL-33-ST2-Wnt/MAPK/NF-κB feedback loop sustaining myeloid leukemia stemness and drug resistance, with Wnt upregulating ST2.

    Evidence Cell lines and patient samples with ST2 surface quantification, multi-pathway signaling assays, LSC in vivo expansion, and drug resistance assays

    PMID:37643244

    Open questions at the time
    • Initiating trigger of the autocrine loop not defined
    • Notch repression mechanism downstream of ST2 incomplete
  31. 2023 High

    Showed that lung-resident CD69+ST2+ TH2 memory cells require ST2/IL-33 (not TSLP) signaling for development and durable recall, establishing ST2's role in tissue-resident memory.

    Evidence Parabiosis, intranasal allergen sensitization, ST2-KO and IL-33-KO mice, and recall challenge experiments

    PMID:36720287

    Open questions at the time
    • Signaling program maintaining tissue residency downstream of ST2 not defined
    • Human relevance not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple IL1RL1 isoforms and the alternative oxidised-IL-33/RAGE/EGFR pathway are integrated and balanced within a single tissue, and the structural basis of ST2L–IL-1RAcP assembly and ligand engagement, remain unresolved.
  • No structural model of the ST2L/IL-1RAcP/IL-33 complex
  • Receptor mediating sST2's direct (non-decoy) profibrotic signaling unidentified
  • Quantitative balance between ST2-dependent and ST2-independent IL-33 signaling in vivo unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0038024 cargo receptor activity 2 GO:0098772 molecular function regulator activity 2 GO:0140313 molecular sequestering activity 2
Localization
GO:0005576 extracellular region 3 GO:0005886 plasma membrane 3
Pathway
R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 3 R-HSA-5357801 Programmed Cell Death 2
Complex memberships
RAGE–EGFR complex (oxidised IL-33, ST2-independent)ST2L–IL-1RAcP receptor complex

Evidence

Reading pass · 32 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 IL-33 is the functional ligand for the transmembrane ST2L receptor; sST2 acts as a soluble decoy receptor that sequesters IL-33 and blocks the antihypertrophic IL-33/ST2L signaling in cardiomyocytes. ST2-knockout mice subjected to pressure overload (transverse aortic constriction) showed more left ventricular hypertrophy, fibrosis, and impaired survival compared to WT, and recombinant IL-33 treatment rescued WT but not ST2-/- mice. ST2-knockout mouse model, transverse aortic constriction pressure overload, recombinant IL-33 treatment, cardiomyocyte hypertrophy assays, NF-κB signaling assays, IκBα phosphorylation measurement The Journal of clinical investigation High 17492053
2007 IL-33/ST2 signaling is mechanically activated: IL-33 is produced predominantly by cardiac fibroblasts in response to biomechanical strain, and signals to cardiomyocytes (which express ST2L), constituting a fibroblast-cardiomyocyte paracrine cardioprotective system. In vitro mechanical stretch of cardiac fibroblasts, immunohistochemistry, cardiomyocyte-fibroblast coculture assays The Journal of clinical investigation High 17492053
2001 ST2V, a third splice variant of the ST2/IL1RL1 gene, localizes to the plasma membrane (not secreted like sST2) and is predominantly expressed in the stomach, small intestine, and colon; subcellular fractionation placed it in the insoluble/membrane fraction. RT-PCR tissue distribution, COS7 transfection, radiolabeling, subcellular fractionation, confocal laser microscopy, monoclonal antibody detection Biochemical and biophysical research communications Medium 11478810
1997 ST2 mRNA and protein expression (both soluble and membrane-anchored isoforms) are induced by pro-inflammatory stimuli (TNF, IL-1α, IL-1β, PMA) in human and murine cells; soluble ST2 expression is inducible while membrane ST2 expression remains constitutive. Northern/Western blotting using ST2 cDNA probes and polyclonal antibody, cytokine and PMA treatment of BALB/c-3T3 cells, UVB irradiation mouse model Biochemical and biophysical research communications Medium 9207179
2013 The membrane-bound ST2L forms a receptor complex with IL-1 receptor accessory protein (IL-1RAcP/IL1RAP) to transduce IL-33 signaling, activating NF-κB and MAPK pathways. IL1RL1 missense variants in the intracellular (TIR) domain increase sST2 expression by inducing IL-33 expression and enhancing IL-33 responsiveness via ST2L. Cell culture model with IL1RL1 missense variant expression, sST2 quantification, GWAS of Framingham Offspring Cohort (n=2,991), functional characterization of SNP effects on IL-33 signaling The Journal of clinical investigation Medium 23999434
2014 IL-33/ST2 axis promotes mast cell survival specifically through the anti-apoptotic molecule BCLXL; ST2-deficient mice had fewer tissue mast cells in inflamed joints, helminth-infected intestine, and normal peritoneum. Peritoneal transfer confirmed a cell-intrinsic ST2 role, with WT mast cells surviving better than ST2-/- mast cells in an IL-33-dependent manner. ST2-knockout mouse model, in vitro apoptosis assay with human and murine mast cells, BCLXL inhibition/knockdown, peritoneal mast cell transfer experiments, flow cytometry, IL-33 blockade Proceedings of the National Academy of Sciences of the United States of America High 24982172
2012 Soluble mST2 protein inhibits Th2 cytokine production (IL-4 and IL-5 but not IFN-γ) from allergen-stimulated splenocytes in vitro and, when transferred in vivo by gene transfer, reduces eosinophil numbers and IL-4/IL-5 levels in bronchoalveolar lavage fluid in a murine asthma model. In vitro splenocyte stimulation assay, in vivo intravenous mST2 gene transfer in OVA-sensitized mice, BAL fluid cytokine/eosinophil quantification Clinical and experimental allergy Medium 12372135
2015 ST2 deficiency in T regulatory (Treg) cells does not impair their accumulation in nonlymphoid organs including visceral adipose tissue, but cell-intrinsic ST2 signaling is required for type 2 cytokine production by VAT-resident Tregs and for limiting IL-17A-producing γδT cells in the CNS during neuroinflammation (EAE model). Conditional ST2 knockout limited to Treg cells (Foxp3-Cre), EAE neuroinflammation model, flow cytometry, cytokine measurement The Journal of experimental medicine High 33095261
2015 ST2 signaling contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis (FHL) in mice: ST2 blockade in perforin-deficient LCMV-infected mice markedly improved survival and reduced IFNγ-producing CD8+ and CD4+ T cells, implicating IL-33/ST2 as an amplifier of immune dysregulation via MyD88-dependent signaling. ST2 blockade in Prf1-/- LCMV-infected mice, survival analysis, flow cytometry for IFNγ-producing T cells, serum IFNγ measurement Blood High 26518437
2017 ST2 receptor is highly expressed on microglia and is upregulated after ischemic stroke (tMCAO). ST2 deficiency shifts microglia/macrophages toward M1 polarization, expands brain infarcts, and exacerbates neurological deficits. IL-33/ST2 signaling stimulates microglial production of IL-10, which is critical for neuroprotection; IL-33 treatment failed to protect IL-10 knockout mice. ST2-knockout mice, tMCAO and permanent MCAO stroke models, intracerebroventricular IL-33 infusion, flow cytometry, in vitro microglial cultures and coculture systems, IL-10 KO mice The Journal of neuroscience High 28389473
2020 TGF-β signaling upregulates IL1RL1 (ST2) expression in ILC2 progenitors and common helper-like innate lymphoid progenitors (CHILP) at least partially through the MEK-dependent pathway, and is required for efficient ILC2 development from progenitors. TGF-β receptor II conditional knockout in bone marrow progenitors, flow cytometry of ILC2 progenitors, MEK inhibition experiments, IL1RL1 mRNA expression measurement Nature communications Medium 31911623
2020 Helminth-derived protein HpBARI binds murine ST2 directly, inhibits cell-surface detection of ST2, prevents IL-33-ST2 interactions, and blocks IL-33 responses in vitro and in vivo. HpBARI_Hom2 binds human ST2 with high affinity and effectively blocks human PBMC responses to IL-33. Protein binding assays, cell-surface ST2 detection, in vitro IL-33 stimulation assays, in vivo mouse model of asthma, human PBMC IL-33 response assays eLife High 32420871
2016 IL1RL1 risk SNPs rs1420101 and rs11685480 act as expression QTLs in airway epithelial cells and distal lung parenchyma respectively (not in whole blood), regulating sST2 production from the lung; the genetically determined plasma sST2 reservoir neutralizes IL-33 activity and these eQTL SNPs additively increase risk of airway type 2 inflammation among asthmatics. eQTL analysis in airway epithelial cells and lung parenchyma, plasma sST2 measurement, IL-33 neutralization assay, genetic association analysis in asthmatic cohorts JCI insight Medium 27699235
2020 IL1RL1 TIR signaling domain haplotype SNPs affect IL-33-driven NF-κB signaling in bronchial epithelial cells without interfering with TLR signaling, providing mechanistic insight into how coding variants alter receptor signaling. Primary bronchial epithelial cell cultures with IL-33 stimulation, NF-κB reporter assays, TLR signaling assays, haplotype analysis JCI insight Medium 32324168
2012 PU.1, an Ets-family transcription factor, directly transactivates the human ST2/IL1RL1 promoter via an Ets-family binding cis-element in mast cells (LAD2) and basophils (KU812); siRNA-mediated knockdown of PU.1 significantly reduced ST2 mRNA levels. Reporter assay with wild-type and mutant ST2 promoter constructs, EMSA to identify PU.1 binding, siRNA knockdown of PU.1 with ST2 mRNA quantification Allergology international Medium 22824976
2018 Lungs are a major source of soluble ST2 (sST2) in heart failure; in an experimental ischemic heart failure model, sST2 increased significantly in lungs from week 1, and primary human type II pneumocytes secrete sST2 in response to mechanical strain. Lung aspirate sST2 levels were dramatically higher in cardiogenic pulmonary edema versus other conditions. Experimental ischemic heart failure model with time-course mRNA/protein quantification, primary human type II pneumocyte strain cultures, sST2 measurement in bronchial aspirates, immunostaining of alveolar epithelium Circulation. Heart failure Medium 30562096
2020 sST2 induces human cardiac fibroblast activation and collagen synthesis via upregulation of neuropilin-1 (NRP-1), a regulator of profibrotic TGF-β1. NF-κB inhibition restored NRP-1 levels and blocked sST2 profibrotic effects; NRP-1 knockdown abolished sST2-induced fibroblast activation and collagen synthesis. Proteomics of human cardiac fibroblasts treated with sST2, NF-κB pharmacological inhibition, NRP-1 siRNA knockdown, exogenous NRP-1 overexpression, pressure overload rat model with sST2/NRP-1 correlation Cells High 32664340
2023 Oxidised IL-33 (IL-33ox, which does not bind ST2) forms a functional complex with RAGE and EGFR on airway epithelium, activating an ST2-independent pathway that impairs epithelial wound closure and induces airway remodelling (increased mucus-producing cells, reduced epithelial defence) mimicking COPD pathology. In vitro epithelial damage assays, 3D air-liquid interface cultures (healthy and COPD), transcriptomics (bulk and single-cell RNA-seq), IL-33-neutralising antibody treatment, co-immunoprecipitation/complex formation of RAGE-EGFR The European respiratory journal High 37442582
2023 IL1RL1 signaling in Treg cells promotes immunosuppression in the tumor microenvironment; IL1RL1+ Treg cells couple with cancer-associated fibroblasts (CAFs) via the amphiregulin (AREG)-EGFR axis, where Treg-derived AREG promotes a profibrotic and immunosuppressive CAF functional state. Blockade of IL1RL1 signaling in Tregs enhanced antitumor activity of IL-33 and PD-1 blockade. Single-cell RNA-seq, in vivo AREG mAb blockade, genetic IL1RL1 deficiency in Tregs, tumor growth experiments, PD-1 combination treatment Science advances Medium 37611111
2019 IL-33/ST2 signaling promotes mast cell (MC) accumulation and ST2-expressing TAM (tumor-associated macrophage) expansion, and in colorectal cancer (CRC) models, ST2+ TAMs are recruited via CXCR3 expression and exacerbate the immunosuppressive TME. ST2 depletion combined with anti-PD-1 resulted in profound CRC growth inhibition. ST2-KO mice, CRC preclinical models, CXCR3 expression analysis, IL-33 trap fusion protein treatment, combination anti-PD-1 therapy, flow cytometry JCI insight Medium 32376804
2019 IL-33/ST2 signaling in glioblastoma cells activates NF-κB and promotes invasion by upregulating tenascin-C (TNC); blocking the IL-33-ST2-NF-κB pathway downregulated TNC production, and TNC knockdown reduced glioma cell invasiveness. IL-33 treatment and knockdown in glioma cells, NF-κB activation assays, TNC expression measurement, invasion assays in vitro and in vivo (xenograft), ST2 blockade Scientific reports Medium 31889095
2019 IL1RL1 is dynamically expressed on Cbfb-MYH11+ leukemia stem cells (LSCs); IL-33 treatment increased serial replating ability and expression of pro-survival proteins in IL1RL1+ cells in vitro, and IL1RL1+ cells survived chemotherapy better than IL1RL1- cells in vivo. Cbfb-MYH11 knock-in mouse model, in vitro IL-33 stimulation with pro-survival protein measurement, in vivo chemotherapy survival comparison of IL1RL1+ vs IL1RL1- sorted cells Scientific reports Medium 30742053
2023 IL-33-ST2 signaling promotes stemness specifically in subtypes of myeloid leukemia cells (CD34+ BCR/ABL1 CML; AML1/ETO, DEK/NUP214 AML) by activating Wnt, MAPK, and NF-κB signaling, and repressing Notch; Wnt signaling in turn upregulates ST2 expression forming a cell-autonomous loop. IL-33-ST2 signaling promoted resistance to nilotinib and standard chemotherapy. Cell lines and patient samples, ST2 surface abundance quantification, Wnt/MAPK/NF-κB/Notch signaling assays, LSC culture and in vivo mouse expansion assays, drug resistance assays Science signaling High 37643244
2023 IL-33/ST2 signaling in endometrial stromal cells inhibits ferroptosis via the P38/JNK pathway, which downregulates the transcription factor ATF3, thereby preventing ATF3-mediated repression of SLC7A11 (system Xc- antiporter), resulting in increased SLC7A11 expression and protection from lipid peroxidation and ferroptosis. Co-culture of endometrial stromal cells with macrophages, IL-33/ST2 stimulation, erastin-induced ferroptosis assay, ATF3 knockdown/overexpression, SLC7A11 quantification, P38/JNK inhibition, endometriosis mouse model with IL-33 antibody and erastin Cell death & disease High 37816731
2023 The IL1RL1 genetic variant rs1921622, located in an enhancer element, downregulates sST2 gene and protein levels; CRISPR-Cas9 genome editing confirmed this regulatory relationship. Reduced sST2 levels lower Alzheimer's disease risk in females carrying APOE-ε4, with sST2 modulating Aβ pathology through microglial activation and Aβ clearance. GWAS, CRISPR-Cas9 genome editing of rs1921622 enhancer, Mendelian randomization, transcriptome analysis, immunohistochemistry in human and mouse brain, microglial activation assays Nature aging High 37117777
2022 Setd2 (H3K36 methyltransferase) epigenetically regulates IL1RL1 (ST2) expression in Treg cells by modulating activity of promoters and intragenic enhancers where H3K36me3 is deposited; Setd2 deficiency in Tregs specifically reduces GATA3+ST2+ intestinal tTreg cells, impairing their suppressive function. Foxp3-Cre Setd2 conditional knockout, flow cytometry, H3K36me3 ChIP analysis, gene expression profiling of IL1RL1 and GATA3, human Treg SETD2 manipulation Nature communications Medium 36463230
2017 IL-33/ST2 pathway induces microglia to express IL-1β, which in turn stimulates IL-33 expression in oligodendrocytes, forming an amplification loop between IL-1β and IL-33 responsible for exacerbated neuroinflammation in experimental cerebral malaria; ST2-deficient mice did not develop cognitive defects or neurogenesis deficits seen in WT infected mice. ST2-knockout mice in P. berghei ANKA infection model, in vitro IL-33/ST2 stimulation of microglia and oligodendrocytes, IL-1β and IL-33 coculture experiments, cognitive testing, hippocampal neurogenesis analysis PLoS pathogens Medium 28448579
2020 Cell-intrinsic ST2 signaling in ILC2s is non-redundant for their activation; conditional ablation of ST2 specifically in ILC2s (using Nmur1 iCre-eGFP) rendered them unresponsive to IL-33 (but not IL-25), reduced IL-5 and IL-13 production, impaired eosinophil homeostasis, blocked ILC2 expansion in allergic lung inflammation, and increased susceptibility to Nippostrongylus brasiliensis infection. Conditional ST2 knockout in ILC2s (Nmur1-iCre), allergic lung inflammation model (papain), N. brasiliensis infection model, flow cytometry, cytokine measurement, eosinophil counting Frontiers in immunology High 37063913
2019 ST2 deficiency in a pressure overload (TAC) model leads to increased periarteriolar fibrosis, while IL-33 deficiency alone does not produce the same phenotype. This dissociation suggests that loss of ST2 signaling (rather than changes in IL-33 expression) drives periarteriolar fibrosis during pressure overload and aging. IL-33-knockout and ST2-knockout mice with TAC pressure overload, aged WT mice, histomorphometric periarteriolar fibrosis quantification, IL-33 and ST2 expression analysis Journal of molecular and cellular cardiology Medium 30763587
2020 Bcl6 and Blimp1 reciprocally regulate the development of ST2+ Treg cells during allergic airway inflammation: Bcl6-deficient Tregs generate twice as many ST2+ Tregs (in a Blimp1-dependent manner); these ST2+ Tregs produce type 2 cytokines and strongly promote allergic airway inflammation, and ST2 is required for this exacerbated phenotype. Bcl6fl/fl Foxp3-Cre and Prdm1fl/fl Foxp3-Cre conditional knockout mice, house dust mite sensitization model, T cell transfer experiments, flow cytometry, cytokine measurement The Journal of allergy and clinical immunology High 32179158
2004 A novel fourth splice variant of the ST2/IL1RL1 gene, ST2LV, was identified in chicken; ST2LV lacks the transmembrane domain of ST2L (due to alternative splicing) and is secreted as a soluble N-glycosylated protein (~69 kDa; ~53 kDa after deglycosylation) into culture supernatant. RT-PCR cloning, COS-7 cell transfection with radiolabeling, peptide-N-glycosidase F treatment, Western blotting Biochimica et biophysica acta Medium 15566939
2023 CD69+ST2+ lung-resident TH2 memory cells develop within 5 days of initial allergen exposure in lung tissue and persist for ≥84 days; their development and long-term memory function require ST2 and IL-33 signaling but not TSLP receptor. These cells rapidly produce type 2 cytokines upon recall challenge without involvement of circulating T cells. Parabiosis model, intranasal OVA/Alternaria sensitization, flow cytometry with in vivo antibody labeling, ST2-knockout and IL-33-knockout mice, recall challenge experiments The Journal of allergy and clinical immunology High 36720287

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. The Journal of clinical investigation 854 17492053
2008 The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature reviews. Drug discovery 649 18827826
2017 The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Frontiers in immunology 498 28484466
2015 The biology of ST2: the International ST2 Consensus Panel. The American journal of cardiology 241 25665766
2012 IL-33/ST2 axis in inflammation and immunopathology. Immunologic research 224 22392053
2018 IL-33/ST2 Axis in Organ Fibrosis. Frontiers in immunology 178 30405626
2017 ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. The Journal of neuroscience : the official journal of the Society for Neuroscience 176 28389473
2014 Association of IL33-IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood. The Journal of allergy and clinical immunology 150 24568840
2013 Decoding asthma: translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. The Journal of allergy and clinical immunology 146 23380221
2004 T1/ST2--an IL-1 receptor-like modulator of immune responses. Cytokine & growth factor reviews 146 15110792
2015 The IL-33/ST2 axis: Role in health and disease. Cytokine & growth factor reviews 140 26271893
2002 Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 124 12372135
2020 Soluble ST2: A complex and diverse role in several diseases. Clinica chimica acta; international journal of clinical chemistry 116 32305537
1997 Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochemical and biophysical research communications 113 9207179
2014 Soluble ST2 in heart failure. Clinica chimica acta; international journal of clinical chemistry 108 25269091
2001 Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochemical and biophysical research communications 106 11478810
2018 The Role of IL-33/ST2 Pathway in Tumorigenesis. International journal of molecular sciences 104 30205617
2010 Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia. European journal of human genetics : EJHG 98 21150878
2013 A novel cardiac bio-marker: ST2: a review. Molecules (Basel, Switzerland) 96 24335613
2013 Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. The Journal of clinical investigation 93 23999434
2014 IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochemical and biophysical research communications 90 25280997
1999 Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 88 10191101
2023 Role of IL-33-ST2 pathway in regulating inflammation: current evidence and future perspectives. Journal of translational medicine 87 38082335
2015 Soluble ST2--analytical considerations. The American journal of cardiology 85 25697919
2011 ST2 and IL-33 in pregnancy and pre-eclampsia. PloS one 82 21949719
2018 Soluble ST2 in Heart Failure. Heart failure clinics 79 29153199
2010 ST2: a novel remodeling biomarker in acute and chronic heart failure. Current heart failure reports 73 20425491
2023 Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex. The European respiratory journal 71 37442582
2015 Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases. Infection and immunity 71 25712928
2014 IL-33/ST2 axis promotes mast cell survival via BCLXL. Proceedings of the National Academy of Sciences of the United States of America 70 24982172
2022 IL-33/ST2 axis in autoimmune disease. Cytokine 65 36041312
2018 Pulmonary Production of Soluble ST2 in Heart Failure. Circulation. Heart failure 61 30562096
2017 Role of the IL-33-ST2 axis in sepsis. Military Medical Research 60 28168040
2019 ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans. Clinica chimica acta; international journal of clinical chemistry 59 31136737
2011 Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. The Journal of allergy and clinical immunology 58 21281963
2021 IL-33/ST2 as a potential target for tumor immunotherapy. European journal of immunology 55 34131922
2020 A helminth-derived suppressor of ST2 blocks allergic responses. eLife 55 32420871
2021 T reg cell-intrinsic requirements for ST2 signaling in health and neuroinflammation. The Journal of experimental medicine 53 33095261
2017 IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria. PLoS pathogens 53 28448579
2016 IL1RL1 asthma risk variants regulate airway type 2 inflammation. JCI insight 53 27699235
2020 TGF-β induces ST2 and programs ILC2 development. Nature communications 52 31911623
2019 ST2/IL-33 signaling in cardiac fibrosis. The international journal of biochemistry & cell biology 52 31561019
2015 ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Blood 52 26518437
2017 Emerging Roles of IL-33/ST2 Axis in Renal Diseases. International journal of molecular sciences 50 28387719
2017 Targeting IL-33/ST2 signaling: regulation of immune function and analgesia. Expert opinion on therapeutic targets 50 29076792
2014 Phenotypic and genotypic association of epithelial IL1RL1 to human TH2-like asthma. The Journal of allergy and clinical immunology 50 25091434
2018 The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? International journal of cardiology 49 29793758
2023 Amphiregulin couples IL1RL1+ regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity. Science advances 48 37611111
2020 Bcl6 and Blimp1 reciprocally regulate ST2+ Treg-cell development in the context of allergic airway inflammation. The Journal of allergy and clinical immunology 47 32179158
2018 IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics. International archives of allergy and immunology 46 29694974
2023 Macrophages originated IL-33/ST2 inhibits ferroptosis in endometriosis via the ATF3/SLC7A11 axis. Cell death & disease 45 37816731
2022 An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease. Nature aging 44 37117777
2004 Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. Biochimica et biophysica acta 42 15566939
2020 ST2 as checkpoint target for colorectal cancer immunotherapy. JCI insight 41 32376804
2017 IL-33/ST2 Pathway as a Rational Therapeutic Target for CNS Diseases. Neuroscience 38 29175156
2017 IL-33-ST2 Axis in Liver Disease: Progression and Challenge. Mediators of inflammation 38 29180837
2018 The IL-33 Receptor ST2 Regulates Pulmonary Inflammation and Fibrosis to Bleomycin. Frontiers in immunology 36 29988569
2018 ST2: Current status. Indian heart journal 36 30122246
2019 The role of the IL-33/ST2 axis in autoimmune disorders: Friend or foe? Cytokine & growth factor reviews 35 31085085
2018 Interleukin-33 and ST2 Signaling in Tumor Microenvironment. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 35 30256696
2023 Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide. Journal of cardiovascular development and disease 34 37998526
2020 Clinical value of soluble ST2 in cardiology. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 34 33049127
2023 The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy. International journal of molecular sciences 33 37240045
2021 Pathophysiologic role of Interleukin-33/ST2 in Sjögren's syndrome. Autoimmunity reviews 33 33476812
2018 Critical Roles of IL-33/ST2 Pathway in Neurological Disorders. Mediators of inflammation 33 29507527
2012 IL1RL1 gene variants and nasopharyngeal IL1RL-a levels are associated with severe RSV bronchiolitis: a multicenter cohort study. PloS one 33 22574108
2025 IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential. Frontiers in immunology 32 39925809
2022 Setd2 supports GATA3+ST2+ thymic-derived Treg cells and suppresses intestinal inflammation. Nature communications 32 36463230
2015 ST2 in stable and unstable ischemic heart diseases. The American journal of cardiology 32 25678392
2020 ST2 Signaling in the Tumor Microenvironment. Advances in experimental medicine and biology 31 32060890
2023 ILC2 require cell-intrinsic ST2 signals to promote type 2 immune responses. Frontiers in immunology 30 37063913
2023 Lung-resident CD69+ST2+ TH2 cells mediate long-term type 2 memory to inhaled antigen in mice. The Journal of allergy and clinical immunology 29 36720287
2015 Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. Molecular and cellular endocrinology 29 25896545
2024 The IL-33/ST2 axis is protective against acute inflammation during the course of periodontitis. Nature communications 28 38548743
2020 Phenotypic and functional translation of IL1RL1 locus polymorphisms in lung tissue and asthmatic airway epithelium. JCI insight 27 32324168
2013 ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice. The Journal of investigative dermatology 27 23633023
2019 IL-33/ST2 axis promotes glioblastoma cell invasion by accumulating tenascin-C. Scientific reports 26 31889095
2018 Genetic regulation of IL1RL1 methylation and IL1RL1-a protein levels in asthma. The European respiratory journal 26 29519908
2022 Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Frontiers in cardiovascular medicine 24 36225958
2017 IL33 and IL1RL1 variants are associated with asthma and atopy in a Brazilian population. International journal of immunogenetics 24 28266165
2022 Profiling of Tregs across tissues reveals plasticity in ST2 expression and hierarchies in tissue-specific phenotypes. iScience 23 36093048
2019 IL1RL1 is dynamically expressed on Cbfb-MYH11+ leukemia stem cells and promotes cell survival. Scientific reports 21 30742053
2018 Interleukin-33 Receptor (ST2) Deficiency Improves the Outcome of Staphylococcus aureus-Induced Septic Arthritis. Frontiers in immunology 21 29867945
2020 Soluble St2 Induces Cardiac Fibroblast Activation and Collagen Synthesis via Neuropilin-1. Cells 20 32664340
2019 Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis. Journal of molecular and cellular cardiology 20 30763587
2019 Correlation of Interleukin-33/ST2 Receptor and Liver Fibrosis Progression in Biliary Atresia Patients. Frontiers in pediatrics 20 31632941
2015 ST2 in Pulmonary Disease. The American journal of cardiology 20 25665765
2015 ST2 and multimarker testing in acute decompensated heart failure. The American journal of cardiology 20 25697917
2012 Involvement of PU.1 in mast cell/basophil-specific function of the human IL1RL1/ST2 promoter. Allergology international : official journal of the Japanese Society of Allergology 20 22824976
2020 The Functional Roles of IL-33/ST2 Axis in Ocular Diseases. Mediators of inflammation 19 32908451
2019 IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review. Medicina (Kaunas, Lithuania) 19 30769901
2016 IL‑33/ST2 pathway in a bleomycin‑induced pulmonary fibrosis model. Molecular medicine reports 19 27358001
2023 The ST2/IL-33 Pathway in Adult and Paediatric Heart Disease and Transplantation. Biomedicines 18 37371771
2018 ST2 regulates bone loss in a site-dependent and estrogen-dependent manner. Journal of cellular biochemistry 18 30011081
2012 The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva medica 18 23229370
2019 The ST2/Interleukin-33 Axis in Hematologic Malignancies: The IL-33 Paradox. International journal of molecular sciences 17 31652497
2023 IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways. Science signaling 16 37643244
2020 Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker. British journal of haematology 16 32039480
2020 Associations of IL1RAP and IL1RL1 gene polymorphisms with obesity and inflammation mediators. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 15 31897507
2020 Interaction between MyD88, TIRAP and IL1RL1 against Helicobacter pylori infection. Scientific reports 15 32985578

Missed literature

Know a paper Affinage missed for IL1RL1? Flag it for the maintainers and the community.

No submissions yet.